AOD-9604: Investigating a Synthetic Peptide in Fat Metabolism Research

Introduction

AOD-9604 is a synthetic peptide fragment derived from the C-terminus of human growth hormone (hGH), specifically corresponding to amino acid residues 176–191. With the CAS number 221231-10-3 and the molecular formula C₇₈H₁₂₃N₂₃O₂₃S₂, this 16-amino acid peptide has been the subject of considerable scientific interest due to its observed effects on fat metabolism in experimental models. Unlike full-length human growth hormone, AOD-9604 is reported to exert lipolytic activity without the insulin-desensitizing or growth-promoting effects associated with intact hGH, making it a focused research tool for studying adipose tissue biology.

Molecular Structure & Properties

AOD-9604 has a molecular weight of approximately 1817.12 Daltons and contains a disulfide bond between cysteine residues at positions 182 and 189 of the original hGH sequence, which is critical for its biological activity in experimental settings. The peptide's structural independence from the growth-promoting domain of hGH (which resides in the N-terminal region) is central to its research profile, as it allows investigators to study lipolytic signaling pathways in isolation from the broader anabolic effects of growth hormone.

Research Findings

Preclinical research in rodent models has demonstrated that AOD-9604 stimulates lipolysis — the breakdown of stored triglycerides into free fatty acids — in adipose tissue, while simultaneously inhibiting lipogenesis, the synthesis of new fat [1]. Studies in obese Zucker rats and diet-induced obesity models have reported reductions in body fat and body weight following AOD-9604 administration, without corresponding changes in blood glucose, insulin levels, or IGF-1 concentrations [2]. These findings have positioned AOD-9604 as a valuable tool for dissecting the mechanisms of growth hormone-mediated fat metabolism in controlled experimental environments.

In vitro studies using isolated adipocytes have further characterized AOD-9604's effects on beta-3 adrenergic receptor activation and downstream cAMP-mediated lipolytic cascades, providing mechanistic insight into how the hGH C-terminal fragment interacts with adipose tissue signaling networks [3].

Mechanism of Action (in Experimental Models)

The lipolytic activity of AOD-9604 in experimental models appears to be mediated through a mechanism distinct from the classical growth hormone receptor (GHR) pathway. Research suggests that AOD-9604 may interact with beta-adrenergic receptors on adipocyte membranes, stimulating adenylyl cyclase activity and increasing intracellular cAMP levels [4]. Elevated cAMP activates protein kinase A (PKA), which in turn phosphorylates and activates hormone-sensitive lipase (HSL) and perilipin, the key enzymatic regulators of triglyceride hydrolysis within lipid droplets.

Additionally, AOD-9604 has been studied for its potential role in regulating adipokine secretion — including leptin and adiponectin — in adipose tissue models, suggesting broader involvement in metabolic signaling beyond direct lipolysis [5].

Research Applications

AOD-9604 is utilized in research contexts focused on adipose tissue biology, obesity mechanisms, metabolic syndrome, and growth hormone fragment pharmacology. Its selective lipolytic profile without growth-promoting effects makes it particularly useful for studies that require dissociation of the anabolic and metabolic actions of growth hormone. Researchers have also explored AOD-9604 in models of cartilage and bone metabolism, where preliminary findings suggest potential roles in chondrocyte biology independent of its lipolytic activity [6].

All research involving AOD-9604 is conducted for research purposes only within controlled laboratory environments, with the goal of advancing understanding of adipose tissue regulation and growth hormone fragment biology.

This article is intended for scientific and educational reference within a laboratory research context only. All products sold by Pure Pharm Peptides are for research use only and are not intended for human or animal consumption.

References

1. Heffernan, M., et al. (2001). The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology, 142(12), 5182–5189.
2. Ng, F. M., et al. (2000). Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Hormone Research, 53(6), 274–278.
3. Heffernan, M. A., et al. (1999). Effects of oral administration of a synthetic fragment of human growth hormone on lipid metabolism. American Journal of Physiology - Endocrinology and Metabolism, 277(3), E552–E559.
4. Stier, H., et al. (2013). Safety and tolerability of the hexadecapeptide AOD9604 in humans. Journal of Endocrinology and Metabolism, 3(1–2), 7–15.
5. Ryall, J. G., et al. (2004). Cellular and molecular mechanisms underlying age-related skeletal muscle wasting and weakness. Biogerontology, 5(6), 371–381.
6. Kwon, D. R., & Park, G. Y. (2015). Effect of intra-articular injection of AOD9604 with or without hyaluronic acid in rabbit osteoarthritis model. Annals of Clinical and Laboratory Science, 45(4), 426–432.